StudyGraphics #VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas September 16, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract Patients with advanced basal cell carcinoma who received radiation therapy are more likely to experience primary resistance to Hedgehog pathway inhibitors #VisualAbstract: Dose-escalated concurrent chemoradiotherapy does not improve survival in locally advanced esophageal cancer #VisualAbstract Venetoclax with dose-adjusted EPOCH-R may be a promising combination therapy for aggressive B-cell lymphoma
